Free Newsletter
SPOTLIGHT: FDA warns J&J unit on heart drug marketing
Free newsletter via e-mail
Tools
Promotional pens and mouse pads landed a Johnson & Johnson unit it hot water with the FDA. The tchotchkes, which featured the heart drug Natrecor, didn't include warnings about its "numerous risks," the agency said. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
